Alectinib is a highly selective inhibitor of anaplastic lymphoma kinase (ALK) which has shown both systemic and central nerve system efficacy in ALK-positive non-small cell lung cancer [70, 105–108]. This evidence concerns the gene ALK and non-small cell lung carcinoma.